(NASDAQ: PMVP) Pmv Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.23%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.8%.
Pmv Pharmaceuticals's earnings in 2026 is -$75,220,000.On average, 7 Wall Street analysts forecast PMVP's earnings for 2026 to be -$69,415,288, with the lowest PMVP earnings forecast at -$78,059,456, and the highest PMVP earnings forecast at -$52,201,794. On average, 6 Wall Street analysts forecast PMVP's earnings for 2027 to be -$54,056,788, with the lowest PMVP earnings forecast at -$60,247,231, and the highest PMVP earnings forecast at -$38,169,053.
In 2028, PMVP is forecast to generate -$38,986,962 in earnings, with the lowest earnings forecast at -$50,817,230 and the highest earnings forecast at -$25,820,242.